<DOC>
	<DOCNO>NCT00402142</DOCNO>
	<brief_summary>1 . To study efficacy therapeutic HIV vaccine consist autologous myeloid dendritic cell pulse ex vivo high dos inactivate autologous HIV-1 , HIV-1 infect patient early stage disease ( CD4 &gt; 450 x 10 6 /L ) . 2 . To analyze HIV-1 humoral cellular immune response induce immune-based therapy .</brief_summary>
	<brief_title>Dendritic Cell Vaccine HIV-1 Infection</brief_title>
	<detailed_description>Our group report recently first human trial 4 therapeutic immunization six-week interval autologous monocyte-derived dendritic cell ( MD-DC ) load heat-inactivated autologous HIV 12 HIV infect patient receive highly active antiretroviral therapy ( HAART ) since early chronic infection . Autologous HIV concentrate plasma ( 1,500 ml ) obtain plasmapheresis 3-month HAART interruption ( STOP1 ) perform 78 week therapeutic immunization , HAART discontinue ( STOP2 ) therapeutic immunization . There decrease set-point plasma viral load ( PVL ) &gt; = 0.5 log 24 week HAART 4 12 patient . In addition , observe significant lengthening mean double time PVL rebound ( p= 0.01 ) , significant decrease area curve PVL rebound ( p= 0.02 ) mean peak PVL ( p= 0.004 ) 12 week STOP 2 compare STOP1 . This virological response associate weak significant increase HIV-1 specific CD4 lymphoproliferative response , change HIV-1 specific CD8+ T-cell responses peripheral blood lymphoid CTL cell immunization . In lymphoid tissue , also observe trend towards well control HIV-1 replication couple increase CD4+ CTL cell . No significant virological immunological change occur control . We show therapeutic vaccine autologous MD-DC pulse heat inactivate autologous HIV-1 feasible , safe well tolerate elicit weak transient cellular immune response HIV , associate partial transient control HIV replication patient . hypothesize DC vaccine pulse high amount autologous virus obtain culture could effective vaccine use .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Confirmed HIV infection CD4 &gt; 450 x 10 6 /L baseline VL &gt; 10,000 c/ml HAART Part I , patient HAART least 6 month Part II , Patients HAART PVL &lt; 200 copies/ml least 6 month Written inform consent . Patients failure HAART Patients B C symptom ( CDC classification 1993 ) . Age &lt; 18 year old . Pregnant breastfeed woman Patients baseline creatinin &gt; 2.5 mg/dl Patients baseline GOT/GPT &gt; 250 UI/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>HIV Infection</keyword>
	<keyword>Dendritic cell vaccine</keyword>
	<keyword>Autologous virus</keyword>
	<keyword>Heat inactivate</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>